
CYBN
Healthcare · Biotechnology · $413.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2025
EPS trend, 90 days to now · +41.5% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2025 | Time not confirmed | -1.33 | -1.39 | -4.6% |
| Jul 1, 2025 | Time not confirmed | -0.02 | -1.46 | -5787.1% |
| Feb 11, 2025 | Time not confirmed | -0.03 | -0.53 | -1915.2% |
| Nov 13, 2024 | Time not confirmed | -0.02 | -2.86 | -11432.3% |
| Aug 8, 2024 | Before the open | -0.02 | -0.02 | 0.0% |
| Jun 25, 2024 | Time not confirmed | -0.03 | -0.03 | -9.3% |
| Feb 14, 2024 | Before the open | -0.04 | -0.09 | -125.0% |
| Nov 13, 2023 | After the close | -0.05 | -0.05 | 0.0% |
| Aug 14, 2023 | Before the open | -0.06 | -0.07 | -16.7% |
| Jun 27, 2023 | After the close | -0.06 | -0.07 | -16.7% |
| Feb 16, 2023 | After the close | -0.06 | -0.06 | 0.0% |
| Nov 14, 2022 | After the close | -0.07 | -0.06 | +14.3% |
| Aug 8, 2022 | After the close | -0.09 |
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The…
| -0.07 |
| +22.2% |
| Jun 22, 2022 | Before the open | -0.10 | -0.10 | 0.0% |
| Feb 10, 2022 | Before the open | -0.10 | -0.10 | 0.0% |
| Nov 15, 2021 | Before the open | -0.10 | -0.11 | -10.0% |
| Aug 13, 2021 | After the close | -0.05 | -0.09 | -80.0% |
| Jun 28, 2021 | Before the open | -0.05 | -0.08 | -60.0% |
| Feb 16, 2021 | After the close | -0.03 | -0.10 | -233.3% |